DYSPORT®

Why Practitioners Choose DYSPORT®

DYSPORT® is frequently selected for its broader diffusion profile. AbobotulinumtoxinA has a lower protein-to-toxin ratio, which allows it to spread over a wider area from the injection site compared with more localized neuromodulators. [1][2] It carries approved indications for glabellar lines, cervical dystonia, and spasticity in adults and pediatric patients. It is frequently evaluated alongside other botulinum toxin products for its distinct diffusion profile and onset characteristics.This makes DYSPORT® particularly well-suited for larger treatment areas, such as the forehead, where broader coverage with fewer injection sites improves treatment efficiency. The same diffusion characteristic requires careful anatomical planning, as wider spread becomes a liability in precision-focused areas. [6] A second clinical differentiator is onset. Studies of abobotulinumtoxinA in glabellar line treatment report that some patients see rapid and effective improvement, in some cases within the first 24–48 hours, and document high satisfaction with treatment response over time. [3][4] Individual responses vary, and no absolute onset claim is appropriate, but an earlier visible effect is of practical relevance for follow-up scheduling and patient management.

Contact Med Supply Solutions About DYSPORT®

Healthcare professionals looking to add DYSPORT® to their practice can contact the Med Supply Solutions team for information on availability, pricing, documentation, and account requirements. Can representatives guide procuring DYSPORT® 300-unit and 500-unit packs for licensed practitioners who are looking to buy DYSPORT® online? Contact the team at Med Supply Solutions for guidance on professional access and current availability.

What Is DYSPORT® Used For?

DYSPORT® works by blocking acetylcholine release at the neuromuscular junction, temporarily reducing targeted muscle activity and softening dynamic wrinkles driven by repeated facial movement. In aesthetic medicine, the sole FDA-approved cosmetic indication is moderate-to-severe glabellar lines in adults under 65. [1] Common off-label aesthetic applications include forehead lines, brow lift, bunny lines, and platysmal bands; practitioners applying DYSPORT® outside labeled indications should follow current clinical evidence, institutional protocols, and applicable regulations. Therapeutically, DYSPORT® is FDA-approved for cervical dystonia in adults and for upper- and lower-limb spasticity in patients 2 years of age and older — extending its clinical relevance to neurologists, physiatrists, and rehabilitation specialists managing movement disorders and muscle overactivity. [1][5] These aesthetic injectable products and therapeutic neurotoxin applications differ significantly from cosmetic protocols in dosing, dilution, injection-site selection, and retreatment intervals; therefore, practitioners should follow product-specific prescribing information for each indication. [1][2]

DYSPORT® Product Presentations

DYSPORT® is supplied in 300-unit and 500-unit vial presentations. The 300-unit vial is standard for most aesthetic protocols, including treatment of the glabellar line. At the same time, the 500-unit presentation is better suited to therapeutic applications, such as spasticity management, or to higher-volume aesthetic practices. [1] Regional packaging varies across international markets. Czech, Slovakian, Korean, and other local-language versions reflect the product's global availability — formulation and specification remain consistent. Still, practitioners receiving non-English packaging should verify product authenticity, expiration date, LOT number, and cold-chain handling documentation before use. DYSPORT® units are not interchangeable with BOTOX®, XEOMIN®, or other botulinum toxin preparations on a 1:1 basis. A commonly referenced conversion estimate is approximately 2.5:1 (DYSPORT® to BOTOX®). Still, this figure varies by indication, injection area, dilution, and practitioner technique — product-specific dosing protocols should always be followed to avoid dosing errors. [7]

DYSPORT® vs BOTOX®

DYSPORT® and the BOTOX® neuromodulator are both botulinum toxin type A products but differ meaningfully in their formulations, unit systems, and clinical behavior. DYSPORT® contains abobotulinumtoxinA, manufactured by Ipsen; BOTOX® contains onabotulinumtoxinA, manufactured by Allergan/AbbVie. Their unit systems are not interchangeable — the commonly referenced conversion is approximately 2.5:1 in DYSPORT®'s favor — and dosing should always follow product-specific labeling and clinical protocols. The most clinically significant difference is diffusion. DYSPORT® spreads over a broader area from the injection point due to its lower protein-to-toxin ratio, which is advantageous for large-surface treatments such as the forehead, where broader muscle coverage is desired. BOTOX® produces a more localized effect, making it the preferred choice for high-precision areas such as periorbital and lip lines, as well as microdosing protocols. Appropriate selection depends on anatomy, indication, desired spread, dilution, dose, and practitioner experience. [6] At onset, dose-escalating studies indicate that abobotulinumtoxinA can produce rapid, visible improvement in treated areas, with some patients responding within the first 24–48 hours. Evidence on relative onset versus onabotulinumtoxinA is mixed across studies, and neither product demonstrates consistent superiority in onset or duration in randomized controlled trials. Both typically last 3–4 months in cosmetic applications, with individual variation across areas and patients. [4]

About DYSPORT®

DYSPORT® is manufactured by Ipsen S.A., a specialty pharmaceutical company headquartered in Paris, France, with roots dating to 1929. Ipsen's portfolio spans neuroscience, oncology, and rare diseases, and DYSPORT® is its botulinum toxin type A product. In the United States, aesthetic distribution is handled by Galderma; distribution arrangements vary across other markets. [2] DYSPORT® (abobotulinumtoxinA) has been used therapeutically in Europe since the early 1990s. It received FDA approval for both cervical dystonia and glabellar lines in 2009, followed by additional therapeutic approvals for adult and pediatric spasticity. Today, DYSPORT® is the second most widely used botulinum toxin type A product globally, available in more than 80 countries and with a strong clinical presence across both aesthetic and therapeutic settings. [1][2]

DYSPORT® Safety Profile

DYSPORT® safety considerations vary by indication, dose, injection site, patient history, and underlying conditions. Practitioners should screen patients carefully, document expected reactions, and monitor for any symptoms that may require follow-up. [1]

• Common aesthetic reactions: May include bruising, swelling, redness, headache, injection-site discomfort, eyelid ptosis, brow asymmetry, or dry eye. These effects are typically temporary and self-limiting. [1]
• Serious risks: Include the distant spread of toxin effects, which are associated with an FDA Boxed Warning. Botulinum toxin effects may spread beyond the injection site and cause symptoms consistent with botulism — including difficulty swallowing, speaking, or breathing — which may occur hours to weeks after injection and require prompt medical evaluation. [1]
• Contraindications and precautions: Include known hypersensitivity to botulinum toxin products, cow's milk protein, or any formulation component, and infection at the proposed injection site. Caution is required in patients with neuromuscular disorders such as myasthenia gravis or Lambert-Eaton syndrome, in those taking aminoglycosides or other drugs that interfere with neuromuscular transmission, and during pregnancy or breastfeeding. [1]

DYSPORT® Regulatory Status

DYSPORT® received FDA approval on April 29, 2009, for cervical dystonia in adults and for the temporary improvement of moderate-to-severe glabellar lines in adults under 65. [1] Subsequent therapeutic approvals include adult upper-limb spasticity (2015), pediatric lower-limb spasticity in patients 2 years and older (2016), and pediatric upper-limb spasticity in patients 2 years and older (2021). The FDA Boxed Warning for distant spread of toxin effects applies to DYSPORT® and all botulinum toxin products. [1] DYSPORT® is available in more than 80 countries and holds CE Mark certification in the European Union. Local regulatory approvals, labeling, and prescribing information vary by market, practitioners should review current local guidance before clinical use.

How Long Does DYSPORT® Last?

DYSPORT® results typically last 2–5 months, depending on treatment area, dose, dilution, injection technique, muscle activity level, and individual patient metabolism. [3][4] Higher-movement areas may show shorter duration, while some patients maintain results longer with repeated treatment. For cosmetic use, many practitioners plan retreatment around the 3- to 4-month mark, though timing should be individualized based on clinical response.

Administration Overview

• DYSPORT® is reconstituted with preservative-free 0.9% sodium chloride before administration, following product-specific dilution guidance. [1]
• It is injected with a fine-gauge needle into targeted muscles according to the indication, anatomy, and dosing protocol.
• Onset may occur within 24–48 hours in some patients, with full effect typically evident within the first week, and the duration may last several months.

FAQs

1. What is DYSPORT® and how does it work?

DYSPORT® is abobotulinumtoxinA, a botulinum toxin type A injectable that temporarily reduces targeted muscle activity by blocking acetylcholine release at the neuromuscular junction. This helps soften dynamic wrinkles or reduce muscle overactivity, depending on the clinical indication. [1]

2. What is DYSPORT® approved for?

In the United States, DYSPORT® has one FDA-approved cosmetic indication: moderate-to-severe glabellar lines in adults under 65. Therapeutic approvals include cervical dystonia in adults and upper and lower limb spasticity in patients 2 years of age and older. Common off-label aesthetic applications include forehead lines and brow lift. Approval dates and specific labeling vary by indication and market. [1][2]

3. How long do DYSPORT® results last?

DYSPORT® results generally last 2–5 months, depending on treatment area, dosage, patient metabolism, and injection technique. Clinical studies support durable improvement in treated areas, with cosmetic results often managed around a 3- to 4-month retreatment interval, though individual response varies. [3]

4. How does DYSPORT® compare to BOTOX®?

DYSPORT® contains abobotulinumtoxinA, while BOTOX® contains onabotulinumtoxinA. The two products have different unit systems, diffusion profiles, and dosing conventions and are not interchangeable on a 1:1 basis. DYSPORT® is associated with broader diffusion; BOTOX® is often selected for more localized precision. Appropriate selection depends on indication, anatomy, and practitioner technique. [1]

5. What is the DYSPORT® unit conversion vs BOTOX®?

A commonly referenced estimate is approximately 2.5:1 for DYSPORT® to BOTOX®, though evidence is insufficient to support a universal fixed ratio — conversion varies by indication, dilution, muscle group, and technique. Practitioners should always use product-specific dosing protocols. [7]

6. Is DYSPORT® safe?

DYSPORT® is generally well-tolerated when administered by trained practitioners in accordance with the labeled protocols. It carries an FDA Boxed Warning for the distant spread of toxin effects, applicable to all botulinum toxin products, which may cause serious symptoms, including difficulty swallowing, speaking, or breathing. Practitioners should screen patients carefully and follow current prescribing information. [1]

7. How can licensed practitioners access DYSPORT®?

Licensed healthcare professionals can contact the team at Med Supply Solutions to learn about DYSPORT® availability, pricing guidance, documentation, and professional account requirements.

Citations

1. Prescribing information. Food and Drug Administration; 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125274s125lbl.pdf
2. Ipsen Biopharmaceuticals, Inc. FDA-Approved For Spasticity & Cervical Dystonia. Dysport HCP. https://www.dysport.com/en-us/hcp
3. Monheit GD, Baumann L, Maas C, Rand R, Down R. Efficacy, Safety, and Subject Satisfaction After AbobotulinumtoxinA Treatment for Moderate to Severe Glabellar Lines. Dermatol Surg. 2020;46(1):61-69. doi:10.1097/DSS.0000000000002013
4. Joseph J, Moradi A, Lorenc ZP, et al. AbobotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines: A Randomized, Dose-Escalating, Double-Blind Study. J Drugs Dermatol. 2021;20(9):980-987. doi:10.36849/jdd.6263
5. Lew MF, Brashear A, Dashtipour K, et al. A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia. Int J Neurosci. 2018;128(7):619-626. doi:10.1080/00207454.2017.1406935
6. Kerscher M, Roll S, Becker A, Wigger-Alberti W. Comparison of the spread of three botulinum toxin type A preparations. Arch Dermatol Res. 2012;304(2):155-161. doi:10.1007/s00403-011-1179-z
7. Yun JY, Kim JW, Kim HT, et al. Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-masked, randomized study. Mov Disord. 2015;30(2):206-213. doi:10.1002/mds.26085

For licensed healthcare professionals only. The content of this page is provided for informational purposes and does not constitute medical advice.